The underlying rationale here is that IGF2BP2 expression was reported to be upregulated in ESCC (10), which was also verified by the present GEPIA analysis, RT-qPCR, and immunoblotting results. Here, IGF2BP2 is linked to esophageal squamous cell carcinoma.